The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

被引：0
|
作者：
Kongju Wu
Ming Yi
Shuang Qin
Qian Chu
Xinhua Zheng
Kongming Wu
机构：
[1] Medical School of Pingdingshan University,Department of Clinical Medicine
[2] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital of Tongji Medical College
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Immunotherapy; PD-1; PD-L1; CTLA-4; Immune checkpoint inhibitor; Combination therapy; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4
    Jing Guo
    Zhonghui Xue
    Lie Wang
    Cellular & Molecular Immunology, 2022, 19 : 861 - 862
  • [42] CTLA-4 and PD-1 pathway blockade: combinations in the clinic
    Callahan, Margaret K.
    Postow, Michael A.
    Wolchok, Jedd D.
    FRONTIERS IN ONCOLOGY, 2015, 4
  • [43] PD-1 and CTLA-4: Two checkpoints, one pathway?
    Walker, Lucy S. K.
    SCIENCE IMMUNOLOGY, 2017, 2 (11)
  • [44] Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors
    Devaux, Alix
    Baurain, Jean-Francois
    CURRENT OPINION IN ONCOLOGY, 2022, 34 (02) : 123 - 130
  • [45] Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.
    Wang, Daniel Ying
    Kim, Dae Won
    Shah, Neil J.
    Conry, Robert Martin
    Mehta, Rutika Jitesh
    Silk, Ann W.
    Zhou, Alice
    Voorhees, Amber L.
    Mckee, Svetlana B.
    Norrell, Jacqueline
    Mehnert, Janice M.
    Puzanov, Igor
    Gibney, Geoffrey Thomas
    Rapisuwon, Suthee
    Eroglu, Zeynep
    Johnson, Douglas Buckner
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis
    Shen, Kaikai
    Cui, Jinggang
    Wei, Yuqing
    Chen, Xiaojun
    Liu, Guohua
    Gao, Xiaolai
    Li, Wei
    Lu, Huiling
    Zhan, Ping
    Lv, Tangfeng
    Lin, Dang
    JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6636 - 6652
  • [47] ADVERSE NEUROLOGIC COMPLICATIONS FOLLOWING IMMUNE CHECKPOINT INHIBITORS FOR TREATMENT OF MELANOMA: COMPARATIVE ANALYSIS OF PD-1 INHIBITOR MONOTHERAPY TO COMBINATION THERAPY WITH CTLA-4 INHIBITORS
    Das, Nikita
    Dhamija, Ravi
    Kaelber, David
    Kelly, Michael
    Xie, Peter
    Reddy, Deven
    NEURO-ONCOLOGY, 2024, 26
  • [48] Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
    Goepfert, Katrin
    Dinsart, Christiane
    Rommelaere, Jean
    Foerster, Friedrich
    Moehler, Markus
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [49] Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
    Qian, Da
    Xu, Yuhao
    Wu, Yihao
    Qiu, Jie
    Hong, Weimin
    Meng, Xuli
    CHINESE MEDICAL JOURNAL, 2023, 136 (14) : 1663 - 1670
  • [50] Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma
    Feng, Zhichao
    Rong, Pengfei
    Wang, Wei
    GUT, 2020, 69 (10) : 1904 - 1906
12345